

**Wright Medical Group N.V.**  
**Reconciliation of Non-GAAP Combined Pro Forma Net Sales to Net Sales**  
(dollars in thousands--unaudited)

	Three months ended			
	June 30, 2015			
	Standalone Wright Medical Group, Inc.	Standalone Tornier N.V., recast <sup>(1)</sup>	Discontinued revenues <sup>(2)</sup>	Non-GAAP combined pro forma net sales
<b>U.S.</b>				
Lower extremities	\$ 42,360	\$ 9,518	\$ (2,930)	\$ 48,948
Upper extremities	4,175	38,525	—	42,700
Biologics	11,281	415	—	11,696
Sports med & other	454	1,606	—	2,060
<b>Total extremities &amp; biologics</b>	<b>58,270</b>	<b>50,064</b>	<b>(2,930)</b>	<b>105,404</b>
Large joint	—	40	(40)	—
<b>Total U.S.</b>	<b>\$ 58,270</b>	<b>\$ 50,104</b>	<b>\$ (2,970)</b>	<b>\$ 105,404</b>
<b>International</b>				
Lower extremities	\$ 12,600	\$ 2,525	\$ —	\$ 15,125
Upper extremities	2,042	18,316	—	20,358
Biologics	5,318	127	—	5,445
Sports med & other	2,190	1,684	—	3,874
<b>Total extremities &amp; biologics</b>	<b>22,150</b>	<b>22,652</b>	<b>—</b>	<b>44,802</b>
Large joint	—	10,465	(10,465)	—
<b>Total International</b>	<b>\$ 22,150</b>	<b>\$ 33,117</b>	<b>\$ (10,465)</b>	<b>\$ 44,802</b>
<b>Global</b>				
Lower extremities	\$ 54,960	\$ 12,043	\$ (2,930)	\$ 64,073
Upper extremities	6,217	56,841	—	63,058
Biologics	16,599	542	—	17,141
Sports med & other	2,644	3,290	—	5,934
<b>Total extremities &amp; biologics</b>	<b>80,420</b>	<b>72,716</b>	<b>(2,930)</b>	<b>150,206</b>
Large joint	—	10,505	(10,505)	—
<b>Total net sales</b>	<b>\$ 80,420</b>	<b>\$ 83,221</b>	<b>\$ (13,435)</b>	<b>\$ 150,206</b>

(1) Legacy Tornier product line sales have been recast to reflect the reclassification of cement, instruments and freight from the historical Tornier product line "Large Joints and Other" to the product line associated with those revenues that will be utilized for future revenue reporting.

(2) To reduce from Tornier's historical sales the U.S. sales associated with Tornier's Salto Talaris and Salto XT ankle replacement products and silastic toe replacement products, and the global sales associated with Tornier's Large Joint business.

**Wright Medical Group N.V.**  
**Reconciliation of Non-GAAP Combined Pro Forma Net Sales to Net Sales**  
(dollars in thousands--unaudited)

	<b>Six months ended</b>			
	<b>June 30, 2015</b>			
	<b>Standalone Wright Medical Group, Inc.</b>	<b>Standalone Tornier N.V., recast <sup>(1)</sup></b>	<b>Discontinued revenues <sup>(2)</sup></b>	<b>Non-GAAP combined pro forma net sales</b>
<b>U.S.</b>				
Lower extremities	84,348	20,961	(6,827)	98,482
Upper extremities	8,049	77,938	—	85,987
Biologics	22,414	878	—	23,292
Sports med & other	945	3,211	—	4,156
<b>Total extremities &amp; biologics</b>	<b>115,756</b>	<b>102,988</b>	<b>(6,827)</b>	<b>211,917</b>
Large joint	—	86	(86)	—
<b>Total U.S.</b>	<b>\$ 115,756</b>	<b>\$ 103,074</b>	<b>\$ (6,913)</b>	<b>\$ 211,917</b>
<b>International</b>				
Lower extremities	24,396	5,127	—	29,523
Upper extremities	3,959	36,431	—	40,390
Biologics	9,810	243	—	10,053
Sports med & other	4,433	3,867	—	8,300
<b>Total extremities &amp; biologics</b>	<b>42,598</b>	<b>45,668</b>	<b>—</b>	<b>88,266</b>
Large joint	—	22,571	(22,571)	—
<b>Total International</b>	<b>\$ 42,598</b>	<b>\$ 68,239</b>	<b>\$ (22,571)</b>	<b>\$ 88,266</b>
<b>Global</b>				
Lower extremities	108,744	26,088	(6,827)	128,005
Upper extremities	12,008	114,369	—	126,377
Biologics	32,224	1,121	—	33,345
Sports med & other	5,378	7,078	—	12,456
<b>Total extremities &amp; biologics</b>	<b>158,354</b>	<b>148,656</b>	<b>(6,827)</b>	<b>300,183</b>
Large joint	—	22,657	(22,657)	—
<b>Total sales</b>	<b>\$ 158,354</b>	<b>\$ 171,313</b>	<b>\$ (29,484)</b>	<b>\$ 300,183</b>

(1) Legacy Tornier product line sales have been recast to reflect the reclassification of cement, instruments and freight from the historical Tornier product line "Large Joints and Other" to the product line associated with those revenues that will be utilized for future revenue reporting.

(2) To reduce from Tornier's historical sales the U.S. sales associated with Tornier's Salto Talaris and Salto XT ankle replacement products and silastic toe replacement products, and the global sales associated with Tornier's Large Joint business.

**Wright Medical Group N.V.**  
**Supplemental Combined Pro Forma Net Sales Information**  
(unaudited)

**Second Quarter 2016 sales growth/(decline)**

<b>Product line</b>	<b>U.S. combined pro forma</b>	<b>Int'l combined pro forma constant currency</b>	<b>Int'l combined pro forma</b>	<b>Global combined pro forma constant currency</b>	<b>Global combined pro forma</b>
Lower extremities	6%	9%	7%	7%	7%
Upper extremities	17%	17%	18%	17%	17%
Biologics	52%	(7%)	(11%)	33%	32%
Sports med & other	5%	(1%)	(2%)	1%	—%
<b>Total net sales</b>	16%	10%	9%	14%	14%

**Six months ended June 26, 2016 sales growth/(decline)**

<b>Product line</b>	<b>U.S. combined pro forma</b>	<b>Int'l combined pro forma constant currency</b>	<b>Int'l combined pro forma</b>	<b>Global combined pro forma constant currency</b>	<b>Global combined pro forma</b>
Lower extremities	9%	10%	8%	9%	9%
Upper extremities	16%	13%	11%	15%	15%
Biologics	50%	(6%)	(10%)	33%	32%
Sports med & other	3%	(3%)	(6%)	(1%)	(3%)
<b>Total net sales</b>	16%	8%	6%	14%	13%

**Wright Medical Group N.V.**  
**Reconciliation of Non-GAAP Adjusted Gross Margins to Gross Profit from Continuing Operations**  
(dollars in thousands--unaudited)

	Three months ended	Six months ended
	June 26, 2016	June 26, 2016
<b>Gross profit from continuing operations, as reported</b>	\$ 121,707	\$ 244,332
Reconciling items impacting gross profit:		
Inventory step-up amortization	10,387	20,616
Product rationalization	1,954	1,954
Transaction and transition costs	—	124
<b>Non-GAAP gross profit from continuing operations, as adjusted</b>	<b>\$ 134,048</b>	<b>\$ 267,026</b>
Net sales from continuing operations	170,716	340,007
<b>Adjusted gross margins from continuing operations</b>	<b>78.5%</b>	<b>78.5%</b>

**Wright Medical Group N.V.**  
**Reconciliation of Non-GAAP Cash Earnings Per Share to Net Loss from Continuing Operations**  
(dollars in thousands, except per share data--unaudited)

	Three months ended	Six months ended
	June 26, 2016	June 26, 2016
<b>Net loss from continuing operations, as reported</b>	\$ (42,031)	\$ (82,223)
Other reconciling items:		
Inventory step-up amortization <sup>(1)</sup>	10,387	20,616
Product rationalization <sup>(1)</sup>	1,954	1,954
Non-cash interest expense on convertible notes	8,240	15,296
Non-cash loss on extinguishment of debt	12,343	12,343
Derivatives mark-to-market adjustments	(16,632)	(23,273)
Transaction and transition costs <sup>(3)</sup>	7,060	17,893
Management changes <sup>(2)</sup>	1,348	1,348
CVR mark-to-market adjustments	1,401	6,725
Contingent consideration fair value adjustment	306	306
Legal settlement <sup>(2)</sup>	1,800	1,800
Costs associated with new convertible debt <sup>(2)</sup>	234	234
IRS settlement <sup>(4)</sup>	(3,073)	(3,073)
Tax effect of reconciling items	(2,132)	(3,321)
<b>Non-GAAP net loss from continuing operations, as adjusted</b>	<b>\$ (18,795)</b>	<b>\$ (33,375)</b>
Add back amortization of intangible assets	7,484	13,941
<b>Non-GAAP cash earnings</b>	<b>\$ (11,311)</b>	<b>\$ (19,434)</b>
Weighted-average basic shares outstanding	102,785	102,745
<b>Non-GAAP cash earnings per share</b>	<b>\$ (0.11)</b>	<b>\$ (0.19)</b>

<sup>(1)</sup> Impacting Gross Profit.

<sup>(2)</sup> Impacting Selling, General, and Administrative expense.

<sup>(3)</sup> Impacting Selling, General, and Administrative expense and Research and Development expense for \$7.0 million and \$0.1 million, respectively, for the three months ended June 26, 2016. Impacting Gross Profit; Selling, General, and Administrative expense; and Research and Development expense for \$0.1 million, \$17.5 million, and \$0.2 million, respectively, for the six months ended June 26, 2016.

<sup>(4)</sup> IRS settlement includes \$0.8 million of interest income and \$2.3 million tax benefit.

**Wright Medical Group N.V.**  
**Reconciliation of Non-GAAP Adjusted EBITDA to Net Loss from Continuing Operations**  
(dollars in thousands --unaudited)

	<b>Three months ended</b>	<b>Six months ended</b>
	<b>June 26, 2016</b>	<b>June 26, 2016</b>
<b>Net loss from continuing operations</b>	\$ (42,031)	\$ (82,223)
Interest expense, net	13,024	24,878
Benefit from income taxes	(3,300)	(4,588)
Depreciation	13,270	26,120
Amortization	7,484	13,941
<b>Non-GAAP EBITDA</b>	<b>\$ (11,553)</b>	<b>\$ (21,872)</b>
<b>Reconciling items impacting EBITDA:</b>		
Non-cash share-based compensation expense	3,056	6,373
Other income, net	(2,061)	(3,129)
Inventory step-up amortization	10,387	20,616
Product rationalization	1,954	1,954
Transaction and transition costs	7,060	17,893
Management changes	1,348	1,348
Legal settlement	1,800	1,800
Costs associated with new convertible debt	234	234
<b>Non-GAAP adjusted EBITDA</b>	<b>\$ 12,225</b>	<b>\$ 25,217</b>